- Home
- YQ vs MDCX Comparison
YQ vs MDCX Comparison
Compare YQ & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- MDCX
- Stock Information
- Founded
- YQ 2012
- MDCX 2008
- Country
- YQ China
- MDCX United States
- Employees
- YQ N/A
- MDCX N/A
- Industry
- YQ Other Consumer Services
- MDCX
- Sector
- YQ Real Estate
- MDCX
- Exchange
- YQ Nasdaq
- MDCX Nasdaq
- Market Cap
- YQ 52.6M
- MDCX 50.8M
- IPO Year
- YQ 2020
- MDCX N/A
- Fundamental
- Price
- YQ $5.00
- MDCX $2.36
- Analyst Decision
- YQ
- MDCX Strong Buy
- Analyst Count
- YQ 0
- MDCX 2
- Target Price
- YQ N/A
- MDCX $23.50
- AVG Volume (30 Days)
- YQ 32.0K
- MDCX 301.7K
- Earning Date
- YQ 12-10-2025
- MDCX 11-12-2025
- Dividend Yield
- YQ N/A
- MDCX N/A
- EPS Growth
- YQ N/A
- MDCX N/A
- EPS
- YQ N/A
- MDCX N/A
- Revenue
- YQ $20,003,071.00
- MDCX N/A
- Revenue This Year
- YQ N/A
- MDCX N/A
- Revenue Next Year
- YQ N/A
- MDCX N/A
- P/E Ratio
- YQ N/A
- MDCX N/A
- Revenue Growth
- YQ N/A
- MDCX N/A
- 52 Week Low
- YQ $1.26
- MDCX $1.79
- 52 Week High
- YQ $6.45
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- YQ 50.54
- MDCX 49.30
- Support Level
- YQ $4.62
- MDCX $2.25
- Resistance Level
- YQ $5.22
- MDCX $2.46
- Average True Range (ATR)
- YQ 0.33
- MDCX 0.19
- MACD
- YQ -0.13
- MDCX -0.01
- Stochastic Oscillator
- YQ 23.24
- MDCX 33.33
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.